RxDoctor Payments Data

Yonghong Huan, MD

Nephrology · Philadelphia, PANPI 1568525269

Payments from drug & device makers

$33,673in general payments, 2019–2025

Across 25 payments — averaging $1346.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$25K
  • Otsuka America Pharmaceutical, Inc.$4K
  • Ironwood Pharmaceuticals, Inc$4K
  • Bayer$215
  • Fresenius USA Marketing, Inc.$179
  • Stemline Therapeutics Inc.$131
  • plus $615 from 6 others

What the payments were for

  • Consulting fees$4,18269%
  • Travel & lodging$1092%
  • Food & beverage$1,74429%
  • Education$100%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,673 in reported general payments places this provider in the 85th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$114,329
Medicare patients
305
Services billed
910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Thiola EcTiopronin22$338,658
VelphoroSucroferric Oxyhydroxide24$54,119
XphozahTenapanor Hcl11$32,699
LokelmaSodium Zirconium Cyclosilicate26$25,080
RenvelaSevelamer Carbonate11$17,384
ProcritEpoetin Alfa13$13,385
Sevelamer Carbonate33$8,435
Potassium Citrate ErPotassium Citrate60$7,633
Calcium Acetate66$3,712
Midodrine Hcl18$2,885
Torsemide154$2,874
Omega-3 Acid Ethyl Esters20$1,040
Allopurinol80$936
Amiloride Hcl35$839
Eplerenone11$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$179$54,11924 claims
AstraZenecaLokelma$24,687$25,08026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →